

Reference:	FOI6886.21
Subject:	Treatment for any diseases
Date of Request:	14 September 2021

Requested:

- In the past 6 months (latest 6 months available) how many patients have received the following treatments (for any disease):
 - Berinert (Human C1-esterase inhibitor)
 - Cinryze (Human C1-esterase inhibitor)
 - Takhzyro (Lanadelumab)
 - Ruconest (Recombinant human C1-esterase inhibitor)
 - Firazyr (Icatibant injection)
 - Lorviqua (Lorlatinib)
- In the past 6 months (latest 6 months available) how many patients have received the following immunoglobulin treatments (for any disease):
 - Cuvitru
 - Gammanorm
 - Gamunex
 - Hizentra
 - Hyqvia
 - Intratect
 - Kiovig
 - Octagam
 - Privigen
 - Subgam

Response:

- Hywel Dda University Health Board (UHB) provides, within the table below, the number of patients that have received the listed treatments, during the period 1 March to 31 August 2021.

Treatment	Number
Berinert (Human C1-esterase inhibitor)	0
Cinryze (Human C1-esterase inhibitor)	0
Takhzyro (Lanadelumab)	0
Ruconest (Recombinant human C1-esterase inhibitor)	0
Firazyr (Icatibant injection)	0
Lorviqua (Lorlatinib)	*

- The UHB provides, within the table below, the number of patients that have received the listed immunoglobulin treatments, during the period 1 March to 31 August 2021.

Treatment	Number
Cuvitru	0
Gammanorm	0
Gamunex	*
Hizentra	0
Hyqvia	0
Intratect	*
Kiovig	0
Octagam	1
Privigen	35
Subgam	0

Where the figures in the tables have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients, due to the low number of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FoIA. This information is protected by the Data Protection Act 2018/General Data Protection Regulations 2016 (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/General Data Protection Regulations 2016 define personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.